HPC
ZYNE

HM Payson & Co’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

HM Payson & Co’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-50
Closed -$64 – 1058
2023
Q3 		$64 Hold
50
– – ﹤0.01% 994
2023
Q2 		$17 Hold
50
– – ﹤0.01% 993
2023
Q1 		$22 Hold
50
– – ﹤0.01% 1017
2022
Q4 		$26 Hold
50
– – ﹤0.01% 927
2022
Q3 		$0 Hold
50
– – ﹤0.01% 1108
2022
Q2 		$0 Hold
50
– – ﹤0.01% 1174
2022
Q1 		$0 Hold
50
– – ﹤0.01% 1177
2021
Q4 		$0 Hold
50
– – ﹤0.01% 1191
2021
Q3 		$0 Hold
50
– – ﹤0.01% 1143
2021
Q2 		$0 Hold
50
– – ﹤0.01% 1196
2021
Q1 		$0 Buy
+50
New +$227 ﹤0.01% 1206

HM Payson & Co's ZYNE Position: Q4 2023 in Review

HM Payson & Co sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 50 shares — an estimated $64 sold.

HM Payson & Co first reported a position in ZYNE in Q1 2021 and held it in 11 quarters. The position peaked at $64 in Q3 2023. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.

  • HM Payson & Co reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
  • HM Payson & Co sold 50 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $64.
  • HM Payson & Co first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2021 and held it in 11 quarters.
  • HM Payson & Co's Zynerba Pharmaceuticals, Inc position peaked at $64 in Q3 2023.
  • 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.

Based on HM Payson & Co's 13F filing for Q4 2023, filed 13 Feb 2024.